AbbVie announced FDA approval of JUVMO (tavapadon), the first selective D1/D5 receptor agonist for adults with Parkinson's disease. The once-daily tablet is supported by Phase 3 TEMPO data showing improved motor control and reduced levodopa dose escalation. AbbVie expects U.S. availability in October 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
